Regional treatment strategies for in-transit melanoma metastasis

Ryan S. Turley, Amanda K. Raymond, Douglas Tyler

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

For in-transit melanoma confined to the extremities, regional chemotherapy in the form of hyperthermic isolated limb perfusion and isolated limb infusion are effective treatment modalities carrying superior response rates to current standard systemic therapy. Despite high response rates, most patients will eventually recur, supporting the role for novel research aimed at improving durable responses and minimizing toxicity. Although the standard cytotoxic agent for regional chemotherapy is melphalan, alternative agents such as temozolomide are currently being tested, with promising preliminary results. Current strategies for improving chemosensitivity to regional chemotherapy are aimed at overcoming classic resistance mechanisms such as drug metabolism and DNA repair, increasing drug delivery, inhibiting tumor-specific angiogenesis, and decreasing the apoptotic threshold of melanoma cells. Concurrent with development and testing of these agents, genomic profiling and biomolecular analysis of acquired tumor tissue may define patterns of tumor resistance and sensitivity from which personalized treatment may be tailored to optimize efficacy. In this article rational strategies for treatment of in-transit melanoma are outlined, with special emphasis on current translational and clinical research efforts.

Original languageEnglish (US)
Pages (from-to)79-103
Number of pages25
JournalSurgical Oncology Clinics of North America
Volume20
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Melanoma
Neoplasm Metastasis
Extremities
temozolomide
Drug Therapy
Neoplasms
Melphalan
Translational Medical Research
Cytotoxins
Therapeutics
DNA Repair
Pharmaceutical Preparations
Perfusion
Research

Keywords

  • In-transit
  • Isolated limb infusion
  • Isolated limb perfusion
  • Melanoma
  • Regional chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Regional treatment strategies for in-transit melanoma metastasis. / Turley, Ryan S.; Raymond, Amanda K.; Tyler, Douglas.

In: Surgical Oncology Clinics of North America, Vol. 20, No. 1, 01.2011, p. 79-103.

Research output: Contribution to journalArticle

Turley, Ryan S. ; Raymond, Amanda K. ; Tyler, Douglas. / Regional treatment strategies for in-transit melanoma metastasis. In: Surgical Oncology Clinics of North America. 2011 ; Vol. 20, No. 1. pp. 79-103.
@article{46bbdc1d2bba4520854838051cc5c09c,
title = "Regional treatment strategies for in-transit melanoma metastasis",
abstract = "For in-transit melanoma confined to the extremities, regional chemotherapy in the form of hyperthermic isolated limb perfusion and isolated limb infusion are effective treatment modalities carrying superior response rates to current standard systemic therapy. Despite high response rates, most patients will eventually recur, supporting the role for novel research aimed at improving durable responses and minimizing toxicity. Although the standard cytotoxic agent for regional chemotherapy is melphalan, alternative agents such as temozolomide are currently being tested, with promising preliminary results. Current strategies for improving chemosensitivity to regional chemotherapy are aimed at overcoming classic resistance mechanisms such as drug metabolism and DNA repair, increasing drug delivery, inhibiting tumor-specific angiogenesis, and decreasing the apoptotic threshold of melanoma cells. Concurrent with development and testing of these agents, genomic profiling and biomolecular analysis of acquired tumor tissue may define patterns of tumor resistance and sensitivity from which personalized treatment may be tailored to optimize efficacy. In this article rational strategies for treatment of in-transit melanoma are outlined, with special emphasis on current translational and clinical research efforts.",
keywords = "In-transit, Isolated limb infusion, Isolated limb perfusion, Melanoma, Regional chemotherapy",
author = "Turley, {Ryan S.} and Raymond, {Amanda K.} and Douglas Tyler",
year = "2011",
month = "1",
doi = "10.1016/j.soc.2010.09.008",
language = "English (US)",
volume = "20",
pages = "79--103",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Regional treatment strategies for in-transit melanoma metastasis

AU - Turley, Ryan S.

AU - Raymond, Amanda K.

AU - Tyler, Douglas

PY - 2011/1

Y1 - 2011/1

N2 - For in-transit melanoma confined to the extremities, regional chemotherapy in the form of hyperthermic isolated limb perfusion and isolated limb infusion are effective treatment modalities carrying superior response rates to current standard systemic therapy. Despite high response rates, most patients will eventually recur, supporting the role for novel research aimed at improving durable responses and minimizing toxicity. Although the standard cytotoxic agent for regional chemotherapy is melphalan, alternative agents such as temozolomide are currently being tested, with promising preliminary results. Current strategies for improving chemosensitivity to regional chemotherapy are aimed at overcoming classic resistance mechanisms such as drug metabolism and DNA repair, increasing drug delivery, inhibiting tumor-specific angiogenesis, and decreasing the apoptotic threshold of melanoma cells. Concurrent with development and testing of these agents, genomic profiling and biomolecular analysis of acquired tumor tissue may define patterns of tumor resistance and sensitivity from which personalized treatment may be tailored to optimize efficacy. In this article rational strategies for treatment of in-transit melanoma are outlined, with special emphasis on current translational and clinical research efforts.

AB - For in-transit melanoma confined to the extremities, regional chemotherapy in the form of hyperthermic isolated limb perfusion and isolated limb infusion are effective treatment modalities carrying superior response rates to current standard systemic therapy. Despite high response rates, most patients will eventually recur, supporting the role for novel research aimed at improving durable responses and minimizing toxicity. Although the standard cytotoxic agent for regional chemotherapy is melphalan, alternative agents such as temozolomide are currently being tested, with promising preliminary results. Current strategies for improving chemosensitivity to regional chemotherapy are aimed at overcoming classic resistance mechanisms such as drug metabolism and DNA repair, increasing drug delivery, inhibiting tumor-specific angiogenesis, and decreasing the apoptotic threshold of melanoma cells. Concurrent with development and testing of these agents, genomic profiling and biomolecular analysis of acquired tumor tissue may define patterns of tumor resistance and sensitivity from which personalized treatment may be tailored to optimize efficacy. In this article rational strategies for treatment of in-transit melanoma are outlined, with special emphasis on current translational and clinical research efforts.

KW - In-transit

KW - Isolated limb infusion

KW - Isolated limb perfusion

KW - Melanoma

KW - Regional chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=78649478314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649478314&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2010.09.008

DO - 10.1016/j.soc.2010.09.008

M3 - Article

VL - 20

SP - 79

EP - 103

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 1

ER -